Call for Business Leaders to Economically Disengage from Russian Industry
Full List of Co-signatories:
Prof Asif Ahmed, Executive Chairman, Mirzyme Therapeutics, Birmingham U.K.; Senior Advisor to the President of the University of Southampton
Manuel Aivado, MD, PhD, President & CEO, Aileron Therapeutics
Jeff Albers, CEO, Blueprint Medicines
Leslie M. Alexandre, DrPH, Former CEO, Life Science Washington
Avinash Amin, M.D., Managing Partner, Madryn Asset Management, LP
Robert Ang, President and CEO, Vor Bio
Fred Aslan, MD, President & CEO, Artiva Biotherapeutics
Bobak Azamian, MD, PhD, CEO, Tarsus Pharmaceuticals
Martin Babler, CEO & President, Alumis
Joel C. Barrish, Ph.D., President and Chief Scientific Officer, Jnana Therapeutics
Jeremy Bender, Day One Biopharmaceuticals
Alon Ben-Noon, CEO, NeuroSense Therapeutics
Karen Bernstein, Ph.D., Chairman, BioCentury Inc.
Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, BioMarin
Kevin Bitterman, Ph.D., Partner, Atlas Venture
Robert I. Blum, President & CEO, Cytokinetics, Inc.
Jeffrey M. Bockman, Ph.D., EVP, Oncology Practice Head, Cello Health BioConsulting
Pieter Boelhouwer, Managing Director, RA Capital
Bruce Booth, Partner, Atlas Venture
Stephen Brady, CEO, Tempest Therapeutics
Diana Brainard, M.D., CEO, AlloVir
Florian Brand, Co-Founder & CEO, atai Life Sciences
Pablo Cagnoni, M.D., President and CEO, Rubius Therapeutics
Michael Calore, Director of Investor Relations, RA Capital Management
Tess Cameron, Principal, RA Capital
John Celebi, CEO, Sensei Biotherapeutics
Adam Chazan, Managing Director, Cowen
Ben Chiarelli, Founder and CEO, Cellibre
Bharatt Chowrira, PhD, JD, President, PureTech Health
Alicia Chung, SVP Strategy & Business Development, Bionaut Labs
Scott Clarke, CEO, Ambagon Therapeutics
Ron Cohen, M.D., President and CEO, Acorda Therapeutics, Inc.
Tony Coles, M.D., CEO, Cerevel Therapeutics
Grace E. Colón, Ph.D., CEO, InCarda Therapeutics
Kara Coluccio, Managing Partner, Perspective Group
John Crowley, Chairman and CEO, Amicus Therapeutics
Karim Dabbagh, PhD, President and CEO, Second Genome, Inc
Annalisa D’Andrea, President and CSO, ImmuneID
Rick Dewey, MD, Head of Genomics Discovery, Foresite Labs
Derek DiRocco, Partner, RA Capital Management
Jacob Donoghue, M.D., Ph.D., CEO, Beacon Biosignals
Ken Drazan, Chairman & CEO, Arsenal Bio
Amy DuRoss, CEO, Vineti
Ramin Farzaneh-Far, M.D., Venture Partner, R.A. Capital Management
Lisa Gable, WSJ best selling author & former US Ambassador
Jason Gardner, CEO and President, Magenta Therapeutics
Deborah S. Geraghty, President and CEO, Anokion
Cristina Ghenoiu, Ph.D., Principal, RA Capital Management, LP
Oleg Gorškov, CEO, Flytein
Nima Farzan, CEO, Kinnate Biopharma
Matt Feresten, BSA, RA Capital Management LP
Jean-Francois Formela, Managing Director, Atlas Venture
Marshall W. Fordyce, M.D., CEO, Vera Therapeutics, Inc.
Jackie Fouse, Ph.D., CEO, Agios Pharmaceuticals
John Fowler, CEO, Kezar Life Sciences
Mohamed A. Genead, MD, CEO & Co-Founder, Aviceda Therapeutics Inc.
Amedee des Georges, Assistant Professor, City University of New York
Michael Gilman, PhD, CEO, Arrakis Therapeutics
Michael Gladstone, Partner, Atlas Venture
Anil K. Goyal, Ph.D., CLP, CEO & Co-founder, IMMvention Therapeutix, Inc.
Daniel Grau, CEO, Avilar Therapeutics
David Grayzel, M.D., Partner, Atlas Venture
Barry Greene, CEO, Sage Therapeutics
Yvonne Greenstreet, CEO, Alnylam Pharmaceuticals
Tim Hamilton, Senior Manager AAV GMP Mfg, Forge Biologics
Matthew Hammond, Ph.D., Principal, RA Capital Management, LP
Faheem Hasnain, Co-Founder, Chairman and CEO, Gossamer Bio
Patrick C. Hines, M.D., Ph.D., Founder and CEO, Functional Fluidics
Steven Holtzman, former CEO, Decibel Therapeutics
Zachary Hornby, President and CEO, Boundless Bio
Allison Jeynes-Ellis, Chief Executive Officer, Avillion
Amit Jolly, Investor, Carpe Biosciences
Wouter Joustra, General Partner, Forbion
Kevin Judice, CEO, DiCE Therapeutics
Jeb Keiper, CEO, Nimbus Therapeutics
Dan Kemp, CEO, Wugen
Gene Kinney, Ph.D., President and CEO, Prothena Corporation plc
Enko N. Kiprilov, MD, Executive Medical Director, Astellas Biopharma
Bryan Kobel, CEO of TC BioPharm (Holdings) PLC
Joseph Kolchinsky, CEO, OneVision Resources
Anurag Kondapalli, Principal, RA Capital Management
Joanne Kotz, CEO, Jnana Therapeutics
Winston Kung, COO and CFO, PMV Pharmaceuticals, Inc.
Jeff Landau, Chief Business Officer, CytomX Therapeutics
Donna L. LaVoie, President & CEO, LaVoieHealthScience
Pablo Legorreta, Founder & Chief Executive Officer, Royalty Pharma
Joseph Lehar, SVP R&D Strategy, Owkin
Josh Lehrer, CEO, GraphiteBio
Andrew Levin, Partner and Managing Director, RA Capital
Mark Levin
Christina Lilliehook, Senior Science Writer, RA Capital Management L.P.
Gail Maderis, President and CEO, Antiva Biosciences, Inc.
Nello Mainolfi, Ph.D., Founder and CEO, Kymera Therapeutics
Mark Manfredi, President and CEO, Ikena Oncology
Alex Martinez-Forte, Analyst, RA Capital Management
Charlie McDermott, Chairman and CEO, Primmune Therapeutics, Inc.
John McHutchison, AO, MD, CEO & President, Assembly Bio
Mark McKenna, Chairman and CEO, Prometheus Biosciences
David Meek, CEO, Mirati Therapeutics
Samantha Miller, MSc, Co-Founder + Co-CEO, Cadence Health
Kenneth I. Moch, President, Euclidean Life Science Advisors, LLC
Susan Molineaux, CEO, Calithera Biosciences
Alain Maiore, Founder and CEO, Mnemo Therapeutics
William J. Newell, CEO, Sutro Biopharma, Inc.
Anat Naschitz, Founder and CEO, 9xchange
Fuad Naser, Ph.D., Associate, RA Capital Management, LP
Bernat Olle, CEO, Vedanta Biosciences, Inc.
Jack O’Meara, CEO, Ochre Bio
Stelios Papadopoulos, Ph.D., Chairman of the Board, Biogen
Ron Park, CEO, Ambys Medicines
Deval Patrick, Co-Director, Center for Public Leadership, Harvard Kennedy School, Director, GBT and Cerevel
Meghan Petrowski, Business Operations Manager/Recruiting Coordinator, RA Ventures (subsidiary of RA Capital Management, LP)
Glenn Pierce, M.D., Ph.D., CSO at Voyager Therapeutics, Inc., Third Rock Ventures
Mark Pruzanski, M.D., former CEO, Intercept
Pawel Przewiezlikowski, Chief Executive Officer, Ryvu Therapeutics, Poland
Andrew Pucher, Chief Executive Officer, Dascena
Michael Raab, President and CEO, Ardelyx
Srinivas Rao, M.D., Ph.D., Cofounder & Chief Scientific Officer, ATAI Life Sciences AG
Sarah Reed, General Counsel, RA Capital Management
Joshua Resnick, M.D., Managing Director, RA Capital
Jason Rhodes, Partner, Atlas Venture
Aaron Ring, M.D., Ph.D., Founder and President, Simcha Therapeutics
Wendye Robbins, M.D., President & CEO, Blade Therapeutics, Inc.
Scott Robertson, Chief Business & Financial Officer, DICE Therapeutics, Inc.
Lynda Romain, Retired Principal, King David Schools, South Africa
Eric Rose, Chief Compliance Officer, RA Capital Management, LP
Adam Rosenberg, Aliada Therapeutics
Arnon Rosenthal Ph.D., Co-Founder & CEO, Alector
Michael Rosenzweig DVM PhD, EIR, RA Ventures
Ed Saltzman, Executive Chairman, Cello Health BioConsulting
Muneer Satter, Manager, Satter Investment Management
George Scangos, Ph.D., CEO, Vir Biotechnologies
John A. Scarlett, M.D., CEO & Chairman, Geron
Laura Shawver, PhD, CEO, Silverback Therapeutics
Zach Scheiner, PhD, Principal, RA Capital Management, L.P.
Eef Schimmelpennink, President and CEO, Lenz Therapeutics
Christian R. Schubert, Entrepreneur in Residence, Atlas Venture
Alpna Seth, Ph.D.
Rajeev Shah, Managing Partner, RA Capital Management, LP
Alvin Shih, MD MBA, President and Chief Executive Officer, Catamaran Bio
Jill Shuman, Principal, Sci-Comm-Network
Simos Simeonidis, Ph.D., Chairman of the Board and Co-Founder, TheraWave Bio
Jeffrey M. Solomon, Chair and CEO, Cowen
Benny Sorensen, M.D., Ph.D., CEO, Hemab Therapeutics, Inc
Errol De Souza, Executive Chairman, Bionomics Ltd.
Otello Stampacchia, Ph.D., Managing Director, Omega Funds
Laura Stoppel, Ph.D., Principal, RA Capital Management, LP
Matthew C Tindall, CEO, Flightpath Biosciences, Inc
Robin Toft, Founder & CEO, Toft Group, a ZRG Company
Tol Trimborn, CEO, CellPoint
Harlan F Weisman, M.D., Executive Chairman, 3DBio Therapeutics
Christoph Westphal, M.D., Ph.D., Co-founder, Longwood Fund
Rick Winningham, Chairman and CEO, Theravance
Avanish Vellanki, CEO, Rain Therapeutics Inc.
Daphne Zohar, Founder & CEO, PureTech Health
Michael Saulnier , CFO, RA Capital Management L.P.
Eric Elenko, Chief Innovation Officer, PureTech Health
David Wambeke, MD, Craig-Hallum
Dr. Justin Nedzesky, University of Washington
Bryan Roberts, Venrock
PJ Anand, CEO, Alcyone Therapeutics, Inc
Tim Walbert, Chairman, President and CEO
Corey Goodman, Managing Partner, venBio Partners
Bassil Dahiyat, President and CEO, Xencor
Deirdre A. Cunnane, Chief Operating Officer/General Counsel, Omega Fund Management
Robert Tepper, Partner, Third Rock Ventures
Burt Adelman, MD, Chairperson and Co-Founder, Verve Therapeutics and Clear Creek Biotherapeutics
Sara Jane Demy, Demy-Colton
Stephen Rapundalo, President and CEO, Michigan Biosciences Industry Association
Ram Aiyar, CEO, Korro Bio
Nancy Lurker, CEO, EyePoint Pharmaceuticals
Jigar Raythatha, Venture Partner, Third Rock Ventures
Dr. Samuel D Waksal, Founder, Kadmon Corporation
Dr. Rebekah Brooks, The Wistar Institute
Reenie McCarthy, CEO, Stealth BioTherapeutics
Rob Perez, Founder and Chairman, Life Science Cares
Doug Doerfler, Founder, President and CEO, MaxCyte
Jay M. Short, PhD, Chairman, CEO, Cofounder, BioAtla, Inc.
Andrew Koven
Sandra Poole, COO, Mythic Therapeutics
Nadir Mahmood, CFO/CBO, Nkarta Therapeutics
Richard Klinghoffer, PhD, CEO, Presage Biosciences, Inc.
Joanna Stanicka, CEO & Co-Founder, Axonis Therapeutics, Inc.
Jeff Livingstone, CEO, Igia Pharmaceuticals
Michael Powell, Executive Partner, Omega Funds
David Meeker, Chairman and CEO, Rhythm Pharmaceuticals
Arjun Goyal, Co-Founder and Managing Director, Vida Ventures
Ray Pressburger, Managing Director
Alex Agulyansky, IIB Solutions LTD
Camille Samuels, Partner, Venrock
Gregory L. Verdine, President and CEO, LifeMine Therapeutics and FOG Pharmaceuticals
Pearl Freier, President, Cambridge BioPartners, Inc.
O. Prem Das, PhD, Principal, Das Advisors
Rosana Kapeller, President and CEO, ROME Therapeutics
Steven Potts, Chief Executive Officer, OncoMyx Therapeutics
Laura Tadvalkar, Ph.D., Principal, RA Capital Management, LP
Mark Rus, President & Chief Executive Officer, Delix Therapeutics
Stephen Farr, President and CEO, Zogenix
Jessica Sagers, Head of Engagement, RA Capital Management
Marcio Souza, President and CEO, Praxis Precision Medicines
John Kollins, Cofounder, President & CEO, Satsuma Pharmaceuticals, Inc.
Glenn Batchelder, Executor Chairman, XyloCor Therapeutics
Dima Kuzmin, Managing Partner, 4BIO Capital
Andrea Rabney, Founder and Chief Executive Officer , Argot Partners
D.A. Wallach, General Partner, Time BioVentures
Stefan Vitorovic, Co-Founder & Managing Director, Vida Ventures
Carolyn Short, President & COO, Cofounder, Himalaya Therapeutics SEZC
Dr. Alise Reicin, President and CEO, Tectonic Therapeutic
Aoife Brennan, CEO, Synlogic
Michael N. Dudley, PharmD, President and CEO, Qpex Biopharma
Matthew Price, Executive VP, COO and co-founder, Phosplatin Therapeutics
Laurent Fischer, MD, CEO, Adverum
Patrick Enright, Managing Director, Longitude Capital
Michael A Schrader, CEO, Vaxess Technologies
Leone Patterson, Chief Financial Officer/Business Officer, Tenaya Therapuetics, Inc.
Brian Lewandowski, Analyst, RA Capital
Thomas Brady, VP, Flow Pharma
Julius Knowles, Partner, Mass General Brigham Ventures
Patrick Nosker, Ph.D., Partner, Affinity Asset Advisors
Clay Thorp, General Partner, Hatteras Venture Partners
Andrew Curtis, CEO, Artelus
Nikhil Bhide, Chief Business Officer, Peptilogics
Christy L. Shaffer, Partner, Hatteras Venture Partners
Gustav A. Christensen, Chairman of the Board, Morphic Therapeutic, Inc
Ramani Varanasi, Former President & CEO, X-Biotix Therapeutics
Ilan Ganot, Founder & CEO, Solid Biosciences
Abbie Celniker, Third Rock Ventures
Amber Brown, Senior Executive Assistant, RA Capital Management, LP
David H. Crean, Managing General Partner, Coast BioVentures
Rich Heyman, Chairman, ORIC Pharma; Chairman, PMV Pharma
David Slack, CEO, Cend Therapeutics, Inc.
Michael Pellini, MD, Managing Director, Section 32, LLC
Andrew Harrison, Managing Partner, Section 32
David Hirsch, Managing Director, Longitude Capital
Michael Gillespie, Associate, RA Capital Management
Sean McCarthy, CEO and Chairman, CytomX Therapeutics
Michaela Schorr, Daycare provider
Edward A Keysor, Chief Operating Officer, Kisbee Therapeutics
Paula Ragan, CEO, X4 Pharmaceuticals
Eileen McCullough, Former CEO, ManaT Bio
Nessan Bermingham, Partner, Khosla Ventures
Mario Barro, Director of Vaccines and Innovation, RA Capital; President, GIVAx
Sean Thompson, Co-Founder & CEO, Psigryph Inc.
Mike Guerra, President & CEO, California Life Sciences
Barbara Weber, Chief Executive Officer, Tango Therapeutics
Travis Whitfill, Partner, Bios Partners
Christopher Ogden, Vice President, Finance and Accounting, CytomX Therapeutics
Ryan Barrett, General Counsel & Lead of Corp. Dev., ATAI Life Sciences NV
Jeffrey Bluestone, CEO and President, Sonoma Biotherapeutics
Nancy Simonian, CEO, Syros Pharmaceuticals
G. Diego Miralles, MD
Zachary Sweeney, CEO, Interline Therapeutics
Krish G Krishnan, CEO, ImmunoHeal Personalised Medicine Pte Ltd, Singapore
Matthew W. Kalnik, PhD, Founding CEO, Antidote Therapeutics, Inc.
Amanda Wagner, Chief Executive Officer, Immunitas Therapeutics
David Steinberg, General Partner, Longwood Fund
Michael Trager, Vice President of Development, Food Allergy Research & Education (FARE)
Robin Qiu, Senior Investment Analyst, Mirae Asset Global Investments
Alicia J Hager, Chief Legal Officer, Nkarta, Inc.
Michelle Doig, Partner, Omega Funds
Douglas Fambrough, former CEO, Dicerna Pharmaceuticals
Paul Bolno, President and CEO, Wave Life Sciences
Philip Ferneau, Managing Partner, Borealis Ventures
Fredrik Wiklund, President & CEO, Bright Peak Therapeutics
Asa Abeliovich, CEO, Leal Therapeutics
Gerald Sewack, Director of Scientific Operations, RA Capital
Nina Labatt, COO & CFO, Section 32
Christy Kuo, Associate , RA Capital
Patrick Arensdorf, Chief Executive Officer, Exai Bio
Alejandro Tocigl, Co-Founder & CEO, Miroculus Inc
Will Patrick, CEO, Culture Biosciences
David Scheer, Chairman of the Board, Adela, Refactor Health, Revelar, BiologicsMD
Cariad Chester, Partner, TCG X
Collin Yang-Wong, Senior Investment Analyst, Foresite Capital
Eli Glezer, CSO, Singular Genomics
Tristan Orpin, President and CEO, Cradle Genomics
George Thampy, Senior Director, Corporate/Business Development, CareDx
Laurie B. Keating, Independent Director, Director of Imago BioSciences, Immuneering Corporation and PepGen
Sumit Aggarwal, President & CEO, Eloxx Pharmaceuticals
Chau Cheng, VP, Investor Relations and Corp Communications, CytomX Therapeutics, Inc.
Joshua Makower, Special Partner, NEA
Ellen Lubman, Chief Business Officer, Werewolf Therapeutics
Chen Yu, Managing Partner, TCG Crossover
Riley Ennis, CPO, Freenome
Perry Karsen, Board Chair
Andreas Buchbender, Healthcare Analyst, Medical Strategy GmbH
Chieze Ibeneche-Nnewihe, PhD, Director of Business Development, BioMarin Pharmaceutical
Tom Zhang, Head of Data, Section 32
Eamon Brady, CEO, WhiteSwell Limited
Elvira Sistac, Quality Assurance, Plásticas Puig Packaging, S.L.
Viraj Pillai, FC
Francesco de Rubertis, Partner, Medicxi
Matthew Foy, Partner, SROne
Ohad Hammer, Partner, Pontifax
Jonathan Montagu, Chief Executive Officer, HotSpot Therapeutics
Hillel Bachrach, Managing Partner, 20 20 HEALTHCARE PARTNERS
Erin Clutter, Head of Graphics, RA Capital
John P Butler, President and CEO, Akebia Therapeutics
David Crowe, Director of Operations, RA Capital Management, L.P.
Peter K Wirth, Chairman, Forma Therapeutics Holdings, Inc.
Steven Nichtberger, CEO, Cabaletta Bio
Daniel Bahcheli, Associate Director, RA Capital Management
Allen Conger, CEO, NeuroMedica, Inc.
Craig Matturro, VP, 1315 Capital
Harvey Chan, Controller, RA Capital Management, LP
Cristina Montero, Associate Director, TechAtlas, RA Capital Management, LP
Peter Balogh, Associate, RA Capital
Peter Smith, President and CEO, Remix Therapeutics
Kate Haviland, Chief Operating Officer, Blueprint Medicines
Jay Skyler, Professor, University of Miami Diabetes Research Institute
Kriti Subramanyam, Associate, RA Capital Management
Shumaila Irshad, Analyst, Deerfield Management
Gregory Mayes, President and CEO, Antios
Saul W Fink, SVP
Monica Stanciu, Associate Director, TechAtlas, RA Capital Management, LP
Eva Jack, Chief Operating Officer, HotSpot Therapeutics
Gerhard Koenig, President & CEO, Arkuda Therapeutics
Sonia Kartha, Associate, RA Capital
Steve Lufkin, CEO, Selux Diagnostics
Arthur Hiller, CEO, Amasa Therapeutics, Inc.
Reid Huber, Partner, Third Rock Ventures
Edward M Kaye, CEO, Stoke Therapeutics
Amir Zamani, Principal, Bain Capital Life Sciences
Emily Minkow, Venture Partner, RA Capital
Christian Cortis, Chief Operating Officer, Tectonic Therapeutic, Inc.
Andrew Fraley, Founder & CTO, Korro Bio
Neil Exter, Partner, Third Rock Ventures
Erich Scheller, Director, TechAtlas, RA Capital
Christopher J Caliri, CIO, RA Capital
Timothy P. Reilly, Chief Development Officer, HotSpot Therapeutics
Tim Clackson, President and CEO, Theseus Pharmaceuticals
Rachel Bedenbaugh, Vaccine Project Manager, RA Ventures/RA Capital
Tillman Gerngross, CEO, Adimab
Kate McKenna, Compliance Coordinator & Paralegal, RA Capital
Nathan Davis, Analyst, RA Capital
Steve Dickman, CEO, CBT Advisors
Craig Randall, Associate Counsel, RA Capital Management, L.P.
Alex Strasser, Associate, RA Capital Management
Peter McNamara, SVP Research, Tectonic Therapeutic
James Schneider, Associate General Counsel, RA Capital Management
Ernesto Gonzalez Jr., Business Analysis Manager, RA Capital
Ana Castro, Research Assistant, RA Capital
Arthur Klausner, President & CEO, Goldilocks Therapeutics, Inc.
Cony D’Cruz, Venture Partner, RA Ventures (RAVen)
Meredith Collins, Research Assistant, RA Capital
Emilie Schleer, Senior Manager, Investor Relations, RA Capital
Maria J. Chiuchiolo, PhD, Senior Director, GIVax at RA Ventures
Robert C. Doebele, CSO, Rain Therapeutics
Dipal Doshi, President and CEO, Entrada Therapeutics
Thomas B King, MBA, Executive Chairman, Concentric Analgesics, Inc.
Astha Bilimoria, Data Analyst Associate, RA Capital Management
Gino Santini, Board Member, Horizon Therapeutics
Thorsten Melcher, Chief Business Officer, RefleXion Medical
Barbara S Fox, CEO, Rheos Medicines
Thomas Culman, Engagement Associate, RA Capital Management
Laura Close, Executive Assistant, RA Capital Management
Jake Simson, Partner, RA Capital Management
Stephanie May, Managing Director & Co-founder, Trophic Communications
Mingfu Zhu, CEO, 20n Bio
Steven Immergut, SVP, Head of Corporate Communications and Investor Relations, Global Blood Therapeutics (GBT)
Russell Greig, CEO and Founder, GBGC, Inc
Jason Tepelmann, Head of IT, CytomX Therapeutics, Inc.
Phi Thach, Executive Assistant, RA Capital
Axel Bolte, CEO and Co-founder, Inozyme Pharma
Kristi Bruno, VP, PR, LaVoieHealthScience
Helen Torley, President and CEO, Halozyme
Lisa Verdi DeScenza, Vice President, Integrated Communications, LaVoieHealthScience
Scott R Pancoast, CEO, Zylo Therapeutics Inc
Ned Scheetz, Managing Partner, Aphelion Capital
Steven Kafka, Managing Partner, Section 32
Cary G Pfeffer, Partner, Third Rock Ventures
James Greenwood, Senior Policy Advisor, DLA Piper
Evan Markegard, Managing Partner, AuGC Partners
Edward P. Monaghan, Ph.D., President, Lusaris Therapeutics, Inc.
Clifford Stocks, Founder and CEO, OncoResponse
David Flores, President & CEO, BioCentury Inc.
Christian Homsy MD, MBA, Chief Executive Officer, Capstan Therapeutics
Harris Kaplan, Managing Partner, Red Team Associates
Robert Kamen, Venture Partner, Third Rock Ventures
Clay B. Siegall, Ph.D., President and Chief Executive Officer, Seagen Inc.
Thomas J. Schall, Ph.D., President, CEO and Chairman, ChemoCentryx
Mahesh Karande, President and CEO, Omega Therapeutics
Stewart J Hen, Managing Partner, Serrado Capital LLC
Lee Cooper, Venture Investments, Leaps by Bayer
Michael Nolan, CEO, Freenome
John Neis, Managing Director, Venture Investors LLC
Wendell Wierenga, Chairman, Crinetics Pharmaceuticals
Mark H Corrigan, President of Research and Development, Tremeau Pharmaceuticals
Jeff Eidel, COO, Cradle Genomics
Amy Peterson, President and Chief Operating Officer, CytomX, Inc
Virginia Paton, Vice President Clinical Science, CytomX
Alison Joly, SVP Program and Alliance Management, CytomX Therapeutics
Llew Keltner, M.D., Ph.D., CEO, EPISTAT
Jeffrey Kane Bischoff, CEO, Old Greenwich Consultants, LLC
Max DeNies, Associate, RA Capital
Fred Guerard, CEO, Graybug Vision
Javier Avendaño, Medical Director, Stoke Therapeutics
Eric Bjerkholt, CFO, Chinook Therapeutics, Inc.
Elaine Caughey, Chief Business Officer, Kymera Therapeutics
Peter Rubin, Executive Director, No Patient Left Behind (NPLB)
Jaime Darce, Director of Immunology, Tectonic Therapeutic
Jeffrey A Douglas, PharmD, Vice President, Clinical Operations, Alumis
Chip Clark, President and CEO, Genocea Biosciences, Inc.
Sara Klein, General Counsel, Alumis Inc.
Steve Vassallo, General Partner, Foundation Capital
Lloyd A. Rowland, Jr., SVP, General Counsel and Chief Compliance Officer, CytomX Therapeutics, Inc.
Abbas Kazimi, Chief Business Officer, Nimbus Therapeutics
Gail Farfel, Chief Development Officer, Zogenix
Sean McAllister, Director of Pharmacology, CytomX Therapeutics
Bret Coons, Director, Corporate Communications, CytomX Therapeutics, Inc.
Laurel Funkhouser, Executive Assistant, Cytomx Therapeutics
Danielle Morelan, Clinical Data Manager I, CytomX Therapeutics
Kenneth Wong, Scientist I, Pharmacology & Toxicology, CytomX Therapeutics
Prince Alexander, Clinical Data Manager, CytomX
Neil Buckley, Chief Development Officer, Lusaris Therapeutics
Standish Fleming, Managing Member, Forward Ventures
Brandon Lam, Scientist II, CytomX Therapeutics, Inc.
Robert Joerres, Director, CMC Operations, CytomX Therapeutics
Norm Enriquez, Vice President, Medical Affairs, CytomX Therapeutics
Scott Harris, COO, Cleave Therapeutics, Inc.
Kate Moreau, Associate Director, RA Capital Management, LP
Janet Souza, Executive Assistant, CytomX Therapeutics
Sunnii Roh, Director of Portfolio Strategy & Corporate Development, PureTech Health
Kana DeLuca, Senior Manager, Investor Relations, PureTech Health
John A. Orwin, President & CEO, Atreca, Inc.
Danielle T Olander-Moghadassian, SVP, Talent and Systems, CytomX
Darrin O. Miles, CEO and President, Nested Therapeutics
Fariba Fischel Ghodsian, Chief Investment Officer, DAFNA Capital Management
Elizabeth Liriano, Office Manger|Executive Assistant, LaVoie Health Science
Jeffrey Kent, Executive Vice President Medical Affairs and Outcomes Research, Horizon Therapeutics
Eric I Richman, CEO, Gain Therapeutics, Inc.
Rohan Palekar, CEO, 89bio
Frank Lee, President and CEO, Forma Therapeutics
Sue Mahony PhD, Independent Board Director, Horizon Therapeutics
David Berry, CEO, Valo Health
Jeff Kindler, CEO, Centrexion Therapeutics
Veronique Moleres, Executive Assistant to CEO, Silverback Therapeutics, Inc.
Ralph Brandenberger, SVP, Technical Operations, Nkarta Therapeutics
Matthew Gline, CEO, Roivant
Vladimir Vexler, CSO , Coherus Biosciences
Klaus Sonnenleiter, CEO, Luftronix, Inc.
Doug Ingram, CEO and President, Sarepta Therapeutics
Kristie Barth, Principal Scientist, Tectonic Therapeutic
Daniel O’Connell, President & CEO, Acumen Pharmaceuticals
Lin Yan, Patent Agent, CytomX
Ivan Ye, Senior Research Associate, CytomX Therapeutics
Seth Harrison, Founder and Managing General Partner, Apple Tree Partners
Elle Millender, Scientist 1, CytomX
Nikolai Eroshenko, PhD, CSO, HelixNano
Peter Marek, Principal Scientist, Tectonic Therapeutic
Sophia C B Jauregui, Executive Assistant
Kartik Ramamoorthi, CEO, Encoded Therapeutics
Aron Jaffe, SVP, Head of Research, Chroma Medicine
Lisa Parks, Managing Partner, MacDougall Advisors, Inc.
David Hanzel, VP & Co-Founder, PRAV (Pan Respiratory AntiViral)
William O. Robb, Partner, Madryn Asset Management, LP
Ed Zhang, CEO, Overland Pharma
Douglas Ingram, CEO and President, Sarepta Therapeutics
Hannu Rajaniemi, CEO, Helix Nanotechnologies Inc (HelixNano)
Marsha Fanucci, Chair, Cyclerion Therapeutics
Geoff MacKay, President & CEO, AVROBIO Inc.
Hank Mansbach, CMO, 89bio
Karen Sharma, Managing Partner, MacDougall Advisors, Inc.
Michael Gray, Chief Financial and Chief Operating Officer, Imara, Inc.
Doug McConnell, CEO, Safi Biosolutions
Neil Desai, Aadi Bioscience Inc
Joseph Toth, Director, Antibody Engineering, Tectonic Therapeutic
Lauren Glaser, SVP Investor Relations and Corporate Affairs, Assembly Biosciences
Ben Zeskind, CEO, Immuneering Corporation
Rosalie Savillo, Purchasing Manager, Silverback Therapeutics
Anthony Johnson, President and CEO, Goldfinch Bio
Brian Cali, Board Member, Jnana Therapeutics
Bruce Goldsmith, President and CEO, Passage Bio
Eric Dube, President & CEO, Travere Therapeutics
Margaret O’Rourke , Partner, Pearl360 Partners, LLC
Heather Mirjahangir Fernandez, CEO, Solv Health
Jeff Huber, Co-Founder & Managing Director, Triatomic Capital
Keith Murphy, CEO, Viscient Biosciences
Tam Dang, Scientist, CytomX
Slavic Voitovych, Head of IoT Business Development, Lemberg Solutions LLC
Thomas Weissensteiner, Medical Writer, Freelance
Rajesh Chopra, Venture Partner, AppleTree Partners
Katie Wood, Consultant Clinical Scientist, CytomX
Kyle Kuvalanka, CFO/COO, Goldfinch Bio
Albert Gianchetti, President & CEO, XyloCor Therapeutics
Owen Smith, Partner, 4BIO Capital
Juliet Anderson, Associate Director, Quality Assurance, Alnylam Pharmaceuticals
Giuseppe Marco Randazzo, Head of AI and Cheminformatics, Endogena Therapeutics
Nicole Alvino, CEO and Founder, Firstup
Daniele Lionetti, Finance Associate, Rejuveron Life Sciences AG
Bina Keshavan, VP Program and Portfolio Management, Ovid Therapeutics
Calvin Nguyen, Director, BD, Gyroscope Therapeutics
Mark Wayne Leuchtenberger, Chairman of the Board of Directors, NeuroSense Therapeutics
Patrick Williams, Associate Director, Executive Search, RA Capital
Laurence Blumberg, MD, President & CEO, Arch Oncology
Stephen Nava, Owner, RAQACS, Inc.
Julia Eastland, CEO, Harpoon Therapeutics
Rob Shaffer, Founder, Enable Therapeutics
Austin Ferrone, Senior Associate, Madryn Asset Management
Nikole E. Kimes, PhD, Siolta Therapeutics, Founder & Chief Executive Officer
David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, Allogene Therapeutics
Arie Belldegrun, M.D., Executive Chairman and Co-Founder, Allogene Therapeutics
Molly McKinney, LaVoieHealthScience
Matthew L Mahoney, Attorney, Law Offices of Matthew L Mahoney
Arthur Franken, General Partner, Investment Director, Gilde Healthcare
Bianca Lombardi, pensionata
Bob Linke, President & CEO, Osmol Therapeutics, Inc.
Ximena Barros, Scientist II, Tectonic Therapeutics
Rick Lundberg, SVP, Corporate Development, Navitor Pharmaceuticals, LLC
Jake Reder, PhD, CEO, Celdara Medical
Aetna Trombley, CEO, Lycia Therapeutics
Wayne Eskridge, CEO, Fatty Liver Foundation
Randolph M. Johnson, Ph.D., Chief Scientific Officer, Angarus Therapeutics
Alyssa Larson, Associate Director, RA Capital
Adrian Dalca, Assistant Professor, Massachusetts General Hospital, Harvard Medical School
Gerry Brunk, Managing Director, Lumira Ventures
Arthur Tzianabos, CEO, Homology Medicines
XinNing Gao, Corporate Controller, Remix Therapeutics
Nikhil Thatte, Principal, Lumira Ventures
Francis Furst Daily IV, Head of Business Development & Corporate Strategy, Praxis Precision Medicines
Liam Scott, Senior Translational Scientist, Praxis Precision Medicines
Timothy Kelly, Chief Financial Officer, Praxis Precisions Medicines
Rachel Surette, Accounting Operations Specialist, Praxis Precision Medicines
Christian Leisner, CEO, CDR-Life
Lauren Mastrocola, VP of Finance, Praxis Precision Medicines
David Chemla-Vogel, Scientist, CytomX Therapeutics
Ahmed Mousa, Chief Business Officer & General Counsel, Pieris Pharmaceuticals
Jim Reddoch, EVP, Research & Investments, Chief Scientific Officer, Royalty Pharma
Kristin DeSouza, Senior Toxicologist, Praxis Precision Medicines
Greg Weaver, CFO, atai Life Sciences
Alex Kane, VP, Investor Relations & Corporate Communications, Praxis Precision Medicines
John K Westwick, Ph.D., CEO, Resonant Therapeutics, Inc.
Corey Puryear, Director, Translational Science, Praxis Precision Medicines
Robert Silverman, CBO, Rejuveron Life Sciences
Jingyao Qiu, Innovation Scout, Rejuveron Life Sciences AG
Donna Ward, Patent Attorney, Founder, DT Ward, PC
Tyler Thompson, Director, Finance, Praxis Precision Medicines
Steven Petrou, CSO, Praxis Precision Medicines
Adam Wright, Global Commercial Lead, Praxis Precision Medicines
Miguel Guzman, Pharmaceutical Development Consultant
Ryan Schubert, Senior Director, Asceneuron
Lorence Kim, Venture Partner, Third Rock Ventures
Johann Chan, Head of CMC Drug Substance, Praxis Precision Medicines
Ferenc Tracik, Chief Medical Officer, Neurosense Therapeutics
Anjali Ganguli, Chief Business Officer, Syndax
Julio Gagne, Vice President Corporate Development, Kite Pharma
Rene Russo, CEO, Xilio Therapeutics
Prashant Bansal, Director, Translational Sciences, Praxis Precision Medicines
Bob Carpenter, Chairman, Olaris Inc., Olaris Inc.
Dan Poscover, CEO, Graticule, Inc.
David Hung, MD, Founder, President and CEO, Nuvation Bio, Nuvation Bio
Alex Nemiroff, General Counsel, Praxis Precision Medicines
Ashley Taylor, Sr Manager, Finance, Praxis Precision Medicines
Tyler Kowalski, Interactive Designer, RA Capital
Anthony Arceci, Associate, RA Capital Management
Lillian Matthews, Senior Medical Writer, Publications Manager, Praxis Precision Medicines
Abhishek Thakar, Data Analyst Associate, RA Capital Management
Tiago Reis Marques, CEO, Pasithea Therapeutics
Greg Dombal, Global Head of Development, Anji Pharmaceuticals
Matt Zuga, CFO/CBO, Acumen Pharmaceuticals
Kaleen Sullivan, Sr Research Coordinator, RA Capital
Klio DiCenzo, Chief People Officer, RA Capital LP
Harim Won, PhD Candidate, Harvard University
Rebecca Silberman, Associate, RA Capital
Debanjan Ray, CEO, Synthekine
Jacki Jenuth, Partner & COO, Lumira Ventures
Mitchell Gold, Chairman and CEO, Alpine Immune Sciences
Rebecca Lucia, Partner, CFO / COO, 5AM Ventures
Andrew Hirsch, CEO, C4 Therapeutics
Bryan Song, Senior Accounting Manager, 5AM Ventures
Suzanne K Wakamoto, SVP, Human Resources, Ovid Therapeutics Inc.
Kellen Robertson, Senior Fund Accountant, 5AM Ventures
Russell L Barton, COO, Acumen Pharmaceuticals
Susan Page, GBT
Walid Gardezi, Managing Partner, Audentix Capital LP
Megan Sniecinski, Chief Business Officer, Praxis Precision Medicines
John Boyce, Co-Founder, Managing Director, Tiger Gene Ventures
Bernard Ravina, Chief Medical Officer, Praxis
Edward van der Horst PhD, SVP, Sensei Biotherapeutics
Chris Morrison, Editor, RA Capital Management
Karl B. Hansen, Chief Technical Operations Officer, Praxis Precision Medicines
Laura Chassaigne, Editor, The Boston Day Book
Douglas A Kerr MD/PhD/MBA, Chief Medical Officer, Generation Bio
Elisabeth Colunio, VP, Human Resources, Sensei Biotherapeutics
Kevin J Harper, CEO, HH Consultancy
Wasim Malik, Managing Partner, Iaso Ventures
Habtamu Maier
Leonid Katz, MD, SVP Clinical Development, Bridgebio
Ebun Garner, General Counsel, Erasca, Inc.
Theresa LoRusso, Principal Owner, Remote Review, LLC
Martin Welschof, President and CEO, BioInvent
Ahmet-Hamdi Cavusoglu
Sascha Berger, Partner, TVM Capital
Adi Hoess, CEO, Affimed NV
Carlo de Notaristefani, Managing Director, CDN Advising LLC
Mohamed Kashkoush, PharmD, Postdoctoral Fellow
Jack Vailas, Senior Associate, RA Capital
Dominic Reynolds, SVP Chemistry, Remix Therapeutics
Dmitry Shvartsman, Chief Technology Officer, Cellaria Inc
Bao Le, VP, Sensei Bio
Frank Sasinowski, Food & Drug Attorney
Clarissa Desjardins, CEO, Congruence Therapeutics
Naheed Kurji, Co-founder, President and CEO, Cyclica
Andy Schwab, Managing Partner, 5AM Ventures
Christina Chiaffarelli, Senior Manager, Clinical Outsourcing, Global Blood Therapeutics
Alison (Ali) Farquhar, Principal, GTL Coaching & Consulting
Chris Palatucci, PhD, Client Partner, Coulter Partners
James Watson, Managing Director, Presidio Partners
Eric Siemers MD, CMO, Acumen Pharmaceuticals
Sara Den Besten, Chief Culture and Engagement Officer, Generation Bio
John Celentano, Founder, J Celentano Advisory Services, LLC
Robert H Pierce, Chief R&D Officer, Sensei Biotherapeutics
Jill Quigley, Biopharma Executive
Rajesh Devraj, President and CEO, Rectify Pharmaceuticals
Mary G, Investor Relations, LaVoieHealthScience
Will Charlton, Vice President, Clinical Development, 89bio
Paul Chun, Managing Partner, Eldred Advisors
Jonathan Lim, Chairman and CEO, Erasca
Scott M. Rocklage, Founding Partner, 5AM Ventures
May Lee, Communications Manager, Numinus Wellness
Janice Hitchcock, Vice President, Regulatory Affairs, Acumen Pharmaceuticals
Johannes Fruehauf, CEO, LabCentral/Biolabs
Rolando Gutierrez-Esteinou, MD, Chief Medical Officer, atai Life Sciences
Robert Shoemaker, SVP, Biology, Erasca, Inc.
Kamila Bajerski, Finance Manager
Tracy Saxton, Managing Director, Dolby Family Ventures
Richard Lam, Principal Scientist, Erasca Inc.
Victor Behar, Director of Intellectual Property, Erasca, Inc.
Errik Anderson, CEO, Chairman and Founder, Alloy Therapeutics
Vidula Dixit-Duarte, Director, Portfolio and Program Management, Erasca
Katherine Terranova, Associate, RA Capital
Karl Bratin, COnsultant, Carnot Pharma and Lusaris
Joseph Nixon, Chief Financial Officer, Locus Biosciences, Inc.
Lilia Koriazova, Sr. Director, Biologics Pharmaceutical Sciences, Erasca Inc.
Vikram Kumar, CEO, Clear Creek Bio
Alissa Coffey, Scientist, Axonis Therapeutics
Shane Hegarty, Chief Scientific Officer & Co-Founder, AXONIS Therapeutics
Paul Simms, CEO, Impatient Health
Kari Edwards, Managing Partner, Harbinger Health
Jean Michel Vernier, VP Chemistry, Erasca
Virginia Burger, CEO, New Equilibrium Biosciences
Tolu Akinola, Director, Product Management
Gordie Nye, CEO, ClearIT, Inc.
Nicholas J. Thomas, Managing Consultant, Pliancy
Graciela Tanjuatco, CRA
Punit Dhillon, CEO & Chair, Skye Bioscience, Inc.
Paula, Chairman of the Board, Ensoma, Ensoma
Bryan Lord, Chief Executive Officer, Pristine Surgical
Raphael Clynes, Vice President, Translational Biology, Xencor, Inc.
Abe Bassan, Principal, Samsara BioCapital
Hans Schikan, Former CEO Prosensa, Co-Founder and Vice-Chairman Pharvaris
Marina Udier, CEO, Nouscom AG
Eric Halioua, CEO, PDC*line pharma SA
Michel Briejer, Managing Director, Thuja Capital Management
Roel Schaapveld, CEO, InteRNA Technologies BV
Neil Butt, Chief Executive Officer, Orbit Discovery
Oscar Miguel Moradei, Senior Directo Medicinal Chemistry, HotSpot Therapeutics
Laurie Halloran, President & CEO, Halloran Consulting Group, Inc.
Evan Friedman, Vice President, Development Operations, HotSpot Therapeutics
Mark Ian Howling, Chairman, TiGL Holdings Limited
Chandra Lovejoy, SVP Regulatory Affairs, Erasca, Inc
Deborah Gan, President, North Star Access Consulting
Dominik Witzigmann, Chief Executive Officer, NanoVation Therapeutics
Charles Banos, Sr. Manager, Finance, Praxis Precision Medicines
Jeanne Bertonis, Chief Operating Officer, Azitra, Inc.
Adam Hill, SVP Platform Integration, HotSpot Therapeutics
Stephen Yoder, President and CEO, Pieris Pharmaceuticals
Gunnar Esiason, Executive Vice President Strategy & Advocacy, Boomer Esiason Foundation
Babita Persaud, Quality Assurance, Amicus Therapeutics
Steven Fried, Scientist, HotSpot Therapeutics
Marcell Zambo, Chief of Staff, Rejuveron Life Sciences AG
John Leonard, Chief Executive Officer, Intellia Therapeutics
Joe Wahle, VP, HotSpot Therapeutics
Adam Simpson, Chief Executive Officer, Icosavax, Inc.
Pamela Carroll, CBO, Roivant Discovery
Daniel E Rosan, Chief Business and Financial Officer, Ascidian Therapeutics
Michael Bailey, President and CEO, AVEO Oncology
Laurence Reid, CEO, decibel therapeutics
Lev Osherovich, Partner, Delin Ventures
William T. Symonds, PharmD, CEO, Altavant Sciences, Inc.
Daniel McIntyre, Founder and Partner, Publick House LLC
Stephanie Maistrellis, CEO & Partner, Lead Life Sciences
Towia Libermann, Associate Professor of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School
Quinton Oswald, Board member and strategic advisor, Opthea, Notal Vision
Michael Varnum, Research Assistant, RA Capital
Praveen Tipirneni, President and CEO, Morphic Therapeutic
Erik Clausen, Managing Partner, CG Life
Harry R Trout III, VP, Finance, ENANTA Pharmaceuticals, Inc
Alistair Duncan, President & CEO, viDA Therapeutics Inc
Mark Walsh, Commercial Director, APC Ltd
Aytug Gencoglu, Staff Engineer, Bio-Rad Laboratories
Dr. Michael Quirmbach, President & CEO , CordenPharma
Gunes Bozkurt, Venture Analyst, RA Capital
Galya Blachman, GC, CCO, 5AM Ventures
Gil Beyen, CEO, ERYTECH Pharma SA
Greg McKee, Co-founder and Managing Director, Torrent Ventures
Wanda I Tormos, Associate Director Chemical Development, Global Blood Therapeutics
Brendan Joyce, Tax Director, RA Capital
Brian Daniels, Partner, 5AM Ventures
Molly Williams, Executive Assistant, Erasca
Alison Milhous, VP, Accounting, Erasca, Inc.
David Chacko, Chief Financial Officer, Erasca
Norbert Bischofberger, Ph.D., President and Chief Executive Officer, Kronos Bio, Inc.
Joanne Oh, Associate Scientist, Erasca, Inc.
Hsin Wang, Research Associate, Cytomx Therapeutics
Peter Greenleaf, CEO, AUPH
Thomas Fuchs, CEO, Cimeio Therapeutics
Che’ Knight, Senior Director, Communications, Ovid Therapeutics
Dan Mandell, Chief Executive Officer, GRO Biosciences
Joana Andoh, Yale School of Medicine
Guevara J Rowand, Sr Director Talent Acquisition, Erasca
Richard Murray, CEO, Jounce Therapeutics
Jennifer A Troia, Chief Human Resources Officer, Assembly Biosciences
Sachin Pai, Erasca
Fang Wang, VP, Oncology, HotSpot Therapeutics
Samantha Singer, President & CEO, Abata Therapeutics
Maria Palasis, President and CEO, Lyra Therapeutics
Philip Moody, Chief Financial Officer, Arthrosi Therapeutics
Jacki Chou, Vice President, PRECISIONheor
Jacob Verghese, Senior Account Director, Trophic Communications
Elliot Levy, Director, Corporate Communications, Global Blood Therapeutics
Frank Stegert, VP, Investment Management and Operations, atai Life Sciences N.V.
Jennifer C Petter, Founder & CIO, Arrakis Therapeutics
Kristen Albright, PharmD, CEO, Prokarium
Livija Deban, PhD, CSO, Prokarium Ltd.
Mark Stephens, Senior Strategic Account Executive, Global Blood Therapeutics
Donald Nicholson, PhD, Board Director & Chairman
Rhea Bisgounis, Recruiting Coordinator, Atlas Venture
Linda Zuckerman, Ph.D., EVP Just-Evotec Biologics, Global Head of Biotherapeutics, Just-Evotec Biologics
Paul Peter Tak, President & CEO, Candel Therapeutics
Florian Schmitzberger, Principal Scientist, Matterhorn Biosciences AG
George Tsiolis, Pharma Marketing Executive, Consultant (Independent)
Fern C. Lazar, Managing Partner, Finn Partners
Edwin Moses, Chairman, Achilles Therapeutics
Leo Rifkind, Director, Charlton Athletic Football Club
Simon Fishel, CEO, ProFaM Ltd
Linda Sierra, SVP, Business Development, Bench International
Terri Hnatyszyn, CEO, E3C, LLC
Patrick Amstutz, CEO
David Berry, Founder & CEO, Valo Health
Sylvia Beaulieu, Director
Paul Edward Buckley, QA Manager, Assembly Biosciences, Inc.
Robb Anderson, Executive Director, Human Resources & Organizational Development, Assembly Bio
Kelly Louie, Senior Manager, Analytical Development & QC, Assembly Biosciences
Heidi Contreras, Scientist II, Assembly Biosciences Inc
Dinara Azimova, Scientist I, Assembly Biosciences
Gerard Ryan, Director, GCP, clinical quality assurance, Assembly Biosciences Inc.
Katie Kitrinos, Vice President, Clinical Virology, Assembly Biosciences
William Delaney, C.S.O., Assembly Biosciences
Asit Parikh, President and CEO, MOMA Therapeutics
Margaret Anne Josephson, VP HR and Operational Services, Retired
Grace Wang, Assembly Biosciences
Paul MacLean, President, ÉEM Environmental & Social Impact Ltd.
Zeenat Patrawala, VP/Director, IQMD
Philip Graham, CDO, Avilar Therapeutics
Chris Varma, CEO, Frontier Medicines
Andrea Patricelli Malizia, CEO, Iama Therapeutics
Shinichi Tamura, Chairman and CEO, Sosei Group Corporation
Inez Wu, Founder & Principal Consultant, Impact Ripple (Hong Kong)
Yury Agroskin, VP of Engineering, Terapore Technology
Martin Freed, Board Director, Solid Biosciences, Avilar Therapeutics
David Klein, CEO, Click Therapeutics, Inc.
Anna Kolchinsky
Michael Ciesielski, PhD, CEO, MimiVax
Eric Rosenblum, Managing Director, Foothill Ventures
Robert Orenstein, VP, Group Director, Paid Search & Social, Interpublic Group
Oleg Grinberg, Managing Director, GIMEG Inc.
Arijit Bose, Chief Scientific Advisor, Audiance, inc.
Peter Blum, Partner, Colrain Capital
Ulrich Neumann, Director, Johnson & Johnson
Gregory Bailey, Chairman, Portage Biotech
Brian Consolazio, Senior Sales Representative, European & Domestic Millwork Division, Grand Banks Building Products
Anatole Klepatsky, COO & Head of BD, Co-founder
Adam Mikkelson
Kristin Rider, Senior Director, Business Development, Curia Global
Lawrence J Zana, President and CEO, Consegna Pharma Inc.
Jasrai Singh Gill, Biotech CMO, practicing MD, Shore Heart Group
Aisha Baro, Executive Director, Life Science Cares Bay Area
Luk H. Vandenberghe, CEO, ciendias bio
Cornelis Been, CEO, Bial Biotech
Lindsay Bourgeois, Lab Director, BioLabs
Armando Cuesta, Managing Partner, Ilana Capital
Glen Giovannetti, Board Director
Klaus Breiner, Managing Partner, Pureos Partners AG
Robert Clarke, PhD, CEO, Kinaset Therapeutics
Hans Herklots, Head LifeSci Advisors Europe, LifeSci Advisors LLC
Michael R. Hufford, PhD, CEO, LyGenesis
Maureen N. Franco, CEO, PRE Commercial
Ali Ardakani, Managing Director, Novareur Ventures Inc.
Ronald M Demuth, CEO, CHEMDIV INC
Michael Liebman, Managing Director, IPQ Analytics LLC
Ester Saxon, Retired
Daniel Ruiz, Chief Operating Officer, Demy-Colton
C. David Pauza, PhD, Chief Science Officer, Viriom, Inc.
Shinichiro Fuse, Partner, TPG Life Sciences Innovation
Peter A. Rowe, Writer
Guy Iannuzzi , CEO, Mentus
Satheesh Ravula, CEO, MD2 Biosciences Inc.
Mark Hasleton, 428 Pharma
Joshua Resnick, Managing Director, RA Capital
Christiani Amorim, Professor, Université Catholique de Louvain
Susan Orr, Chief Medical Officer, Claris Biotherapeutics
Marianna Feretzaki, Head of Discovery Biology, Rejuveron Life Sciences AG
Alexander Margulis, Chief Operating Officer, MANSFIELD Bio-Incubator
Tim Knotnerus, CEO, AgomAb Therapeutics
Philip Vickers, CEO, Faze Medicines
Raymond Stevens, CEO, ShouTi Pharma
Andrew Morton, VP, Finance, HotSpot Therapeutics, Inc
Jason Deer, Director, Corporate Development, Assembly Biosciences, Inc.
Karen McGovern, VP, External Innovation, Ikena Oncology
Brian Bloom, Chairman & CEO, Bloom Burton & Co.
Norman C. Selby, Vice Chairman, Real Endpoints llc
Dennis S France, Senior Director of Business Development, Worldwide Clinical Trials
Barbara Brunnhuber, Chief Executive Officer, Mireca
Michael Samar, CFO, Assembly Biosciences, Inc.
Rachel Mika Dorin, CEO, TeraPore Technologies
Kelly LaPrade, Accountant, OneVision Resources, Inc.
Isaac Middendorf, Director, Program Management, Erasca, Inc.
Anthony D Saleh, Founder & CEO, miRecule, Inc.
Steve Hoerter, President and CEO, Deciphera
Ashlynn Dundon, Clinical Trial Manager, Assembly Biosciences
John Houston, CEO, Arvinas
Pascal Touchon, CEO, Atara Biotherapeutics
Jodi Andrews, CEO ProTrials Research, Inc., ProTrials Research, Inc.
Kristi Wynn
Theodore R Schroeder, CEO, Nabriva Therapeutics
Michael Walker, Executive Director Medicinal Chemistry, Assembly Biosciences
Dina Radenkovic, Co-founder & CEO, Gameto Inc
Ivan Liachko, CEO, Phase Genomics
Jolyon Burton, President & Head of Investment Banking, Bloom Burton & Co.
Peter Sorantin, Founder & CEO, Sorantin Outcomes LLC
Kathryn Whitney, Director
Peter Strumph, CEO, Parvus Therapeutics
Dawn M McLaughlin, Retired Account Representative
Onno van de Stolpe, CEO, Galapagos
Michael C. Chen, Head of Innovation, PureTech Health
Andrew Coleman, Scientist, Aclys Bio
Katie Zomorodi, Executive Director, Assembly Bioscience Inc
Michael William Nall, Former President and CEO, Board Member
Paul Daruwala, COO, Cidara Therapeutics
Maria C. Hernandez, Research Associate, Cidara Therapeutics
Bob Deresiewicz (signing in my individual capacity)
Christine O’Brien, CEO, Tizona Therapeutics
Brian Taylor “BT” Slingsby, Founder & Managing Partner, Catalys Pacific
Shannon McIntee, Employer Brand Manager, Real Chemistry
Takeshi Takahashi, Managing Partner, Catalys Pacific
Taylor Sandison, Chief Medical Officer, Cidara Therapeutics
Manmeet S. Soni, President, Reata Pharmaeuticals, Inc.
Garth Russell, Managing Director
Jeffrey Levitt, General Counsel and Chief Compliance Officer, Stemline Therapeutics
Laurie Stelzer, CFO, Arena Pharmaceuticals
Jolanta Wodzinska, Co-Owner and Director, Business Development, Acanthus Research Inc.
Patricia Sinatra, Principal, Vector Strategic Advisors
Michelle Greenman, Vice President, Regulatory Affairs, Kezar Life Sciences
Dallas Webb, Portfolio Manager, BB Biotech
William Canestaro, Managing Director, Washington Research Foundation/WRF Capital
Michael Christiano, CBO, Broad Institute of MIT and Harvard
Daniel A. de Boer, CEO, ProQR Therapeutics
Valerie Bowling, Executive Director, Conference Forum
Bernard Davitian, Omega Funds
Theresa Heath, Vice President Business Development, LabConnect
Ben Dake, President, Aerovate Therapeutics
Kenneth Galbraith, Chair and Chief Executive Officer, Zymeworks
Maxim Puchkov, CEO, CINCAP LLC
Dr. Trevor P Castor, CEO, Aphios Corporation
Leo Greenstein, CFO, Tarsus Pharmaceuticals, Inc.
G N Edgar, Catalyst Pharmaceuticals
Thomas Malcolm, Founder, President, CSO, Caravan Biologix
Frank Watanabe, President and CEO, Arcutis Biotherapeutics, Inc.
Bonnie Kelly, Strategic Talent Acquisition, Chroma Medicine
Chris Kuehn, Sr. Manager, Project Management, Artiva Biotherapeutics
Nancy Lacoste, Managing Director, Pharma Sales Associates
Misha Petkevich, CIO, V2M Capital
James J Lantry, Lobbyist, California Legislative Advocates
Gero Brockhoff, Research Group Leader, University of Regensburg, Germany
Ira Male, Healthcare Associate, RA Capital
Vas Bailey, Senior Partner, ARTIS Ventures
Timothy E Morris, COO/CFO, Humanigen, Inc.
Francisco Salva, CEO, Azitra, Inc.
Nadim Shohdy, PhD, Entrepreneur in Residence, RA Capital
Igor Fedorov, Doctor of Clinical Pharmacologist
Adam Gridley, President & CEO, Allay Therapeutics
Richard Zwickel, Chairman & CEO, POCN GROUP
Jon Williams, CEO, Lumanity
H. Martin Seidel, CEO, IFM Therapeutics
David Kirn, CEO, 4D Molecular Therapeutics
Matthew Roden, PhD, President and CEO, AKTIS Oncology
Thomas Kledal, CEO, Synklino
Morten Hagelsten Jacobsen, Owner, Tracer Pharma ApS
Torsten M. Madsen, CEO, Hoba Therapeutics
Uffe Boesen, CEO, Xplico ApS
Preben Bruun-Nyzell, CEO, 2N Pharma
Morten Munk, Director, Global Alliance Management, Fujifilm Diosynth Biotechnologies
Mai-Britt Zocca, CEO, IO Biotech
Pek Lum, CEO, Auransa
Inmaculada Silos-Santiago, Founder, ISS BioTech Consulting
